COVID-19肺部超声表现的观察者间一致性
本研究于2020年3月至6月开展,9名来自3个医疗中心的医生(4名住院医师、5名急诊医学医师)独立评估20例经RT-PCR确诊COVID-19患者的肺部超声扫描(共180次独立观察),图像随机选自急诊科便携超声数据库。结果显示B线有无及≥3条B线、正常肺部超声的观察者间一致性较高(κ=0.72-0.79),实变、胸膜下实变及积液为中等一致性(κ=0.49-0.57),胸膜增厚一致性一般(κ=0.23)。
要点
- B线有无(κ=0.79)及≥3条B线(κ=0.72)一致性较高,是较可靠的COVID-19肺部超声征象。
- 正常肺部超声判断一致性较高(κ=0.79)。
- 实变、胸膜下实变及积液为中等一致性(κ=0.49-0.57),胸膜增厚一致性一般(κ=0.23)。
核心结论
- COVID-19的多种肺部超声表现在不同专科医师使用不同便携设备时呈现中等至较高观察者间一致性。
- 最可靠的肺部超声表现可能包括B线的有无/计数或判断扫描是否正常。
- 对于实变等可靠性较低的表现,COVID-19肺部超声临床方案可能需要额外观察者进行确认。
研究设计与样本
- 研究于2020年3月至6月开展,9名医师(住院医师4名、急诊医学医师5名)来自3个医疗中心,独立评估20例经RT-PCR确诊COVID-19患者的肺部超声扫描,共180次独立观察。
- 扫描图像随机选自急诊科使用便携超声设备评估的COVID-19患者图像数据库,医师对患者信息及既往肺部超声判读设盲,采用Kappa值计算观察者间一致性。
关键影像表现/征象
- 正常肺部超声(κ=0.79,95%CI:0.72-0.87)、B线存在(κ=0.79,95%CI:0.72-0.87)、观察到≥3条B线(κ=0.72,95%CI:0.64-0.79)一致性较高。
- 任何实变(κ=0.57,95%CI:0.50-0.64)、胸膜下实变(κ=0.49,95%CI:0.42-0.56)、积液存在(κ=0.49,95%CI:0.41-0.56)一致性中等。
- 胸膜增厚(κ=0.23,95%CI:0.15-0.30)一致性一般。
诊断标准与关键数值
- 采用Kappa值(κ)评估观察者间一致性。
- 正常肺部超声κ=0.79(95%CI:0.72-0.87);B线存在κ=0.79(95%CI:0.72-0.87);≥3条B线κ=0.72(95%CI:0.64-0.79)。
- 任何实变κ=0.57(95%CI:0.50-0.64);胸膜下实变κ=0.49(95%CI:0.42-0.56);积液存在κ=0.49(95%CI:0.41-0.56);胸膜增厚κ=0.23(95%CI:0.15-0.30)。
临床应用与阅片要点
- COVID-19肺部超声方案中,B线有无/计数及判断扫描是否正常可能是较可靠的指标。
- 对于实变等可靠性较低的表现,临床方案可能需要额外观察者进行确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Lung ultrasound (LUS) has received considerable interest in the clinical evaluation of patients with COVID-19. Previously described LUS manifestations for COVID-19 include B-lines, consolidations, and pleural thickening. The interrater reliability (IRR) of these findings for COVID-19 is unknown.
METHODS: This study was conducted between March and June 2020. Nine physicians (hospitalists: n = 4; emergency medicine: n = 5) from 3 medical centers independently evaluated n = 20 LUS scans (n = 180 independent observations) collected from patients with COVID-19, diagnosed via RT-PCR. These studies were randomly selected from an image database consisting of COVID-19 patients evaluated in the emergency department with portable ultrasound devices. Physicians were blinded to any patient information or previous LUS interpretation. Kappa values (κ) were used to calculate IRR.
RESULTS: There was substantial IRR on the following items: normal LUS scan (κ = 0.79 [95% CI: 0.72-0.87]), presence of B-lines (κ = 0.79 [95% CI: 0.72-0.87]), ≥3 B-lines observed (κ = 0.72 [95% CI: 0.64-0.79]). Moderate IRR was observed for the presence of any consolidation (κ = 0.57 [95% CI: 0.50-0.64]), subpleural consolidation (κ = 0.49 [95% CI: 0.42-0.56]), and presence of effusion (κ = 0.49 [95% CI: 0.41-0.56]). Fair IRR was observed for pleural thickening (κ = 0.23 [95% CI: 0.15-0.30]).
DISCUSSION: Many LUS manifestations for COVID-19 appear to have moderate to substantial IRR across providers from multiple specialties utilizing differing portable devices. The most reliable LUS findings with COVID-19 may include the presence/count of B-lines or determining if a scan is normal. Clinical protocols for LUS with COVID-19 may require additional observers for the confirmation of less reliable findings such as consolidations.
引用
- Kumar A, Weng Y, Graglia S, et al. Interobserver Agreement of Lung Ultrasound Findings of COVID-19. J Ultrasound Med. 2021. PMID: 33426734. doi:10.1002/jum.15620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。